{"nctId":"NCT03154125","briefTitle":"Sayana® Press Extension Study","startDateStruct":{"date":"2017-09-22","type":"ACTUAL"},"conditions":["Contraception"],"count":750,"armGroups":[{"label":"Abdomen","type":"EXPERIMENTAL","interventionNames":["Drug: Sayana® Press"]},{"label":"Upper thigh","type":"EXPERIMENTAL","interventionNames":["Drug: Sayana® Press"]},{"label":"Back of the upper arm","type":"EXPERIMENTAL","interventionNames":["Drug: Sayana® Press"]}],"interventions":[{"name":"Sayana® Press","otherNames":["medroxyprogesterone acetate (MPA) injectable suspension"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* not pregnant and no desire to become pregnant in the next 18 months\n* regular menstrual cycles (25 to 35 days in length when not using hormonal contraception, pregnant, or lactating)\n* at risk of pregnancy (no diagnosis of infertility, no history of tubal ligation or hysterectomy, and an average of 1 or more unprotected acts of vaginal intercourse per month)\n* in good general health as determined by a medical history\n* 18 to 35 years of age, inclusive\n* willing to provide informed consent, follow all study requirements, and rely on Sayana® Press injected every 4 months as the only means of contraception for 12 months\n* has only one sexual partner and expects to have that same sexual partner for the next 12 months\n\nExclusion Criteria:\n\n* has a primary partner who has received a vasectomy or is otherwise sterile\n* medical contraindications to depot medroxyprogesterone acetate (DMPA) per World Health Organization medical eligibility criteria for contraceptive use\n* known HIV-infection (for her or her partner)\n* diagnosis or treatment for a sexually transmitted infection in the past month (for her or a partner), excluding recurrent herpes or condyloma\n* received an injection of a progestin-only containing contraceptive (DMPA or norethisterone enanthate) in the past 12 months\n* received an injection of a combined injectable contraceptive in the past 6 months\n* known or suspected allergic reaction to DMPA\n* used a levonorgestrel-releasing intrauterine system, NuvaRing, contraceptive patch, oral contraceptives or a contraceptive implant in the 7 days prior to enrollment (PK cohort only)\n* previous (within 1 month prior to enrollment), current or planned (in the next 12 months) use of an investigational drug, prohibited drug per protocol or other drug which in the opinion of the site investigator could complicate study findings\n* has been pregnant in the past month\n* is lactating\n* plans to move to another location in the next 12 months\n* has a social or medical condition which in the opinion of the site investigator would make study participation unsafe, or interfere with adherence to protocol requirements.","healthyVolunteers":true,"sex":"FEMALE","genderBased":true,"minimumAge":"18 Years","maximumAge":"35 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Occurrence of Pregnancy","description":"Pregnancy is defined as having a positive urine pregnancy test. Positive urine tests will be confirmed by ultrasound and/or serum hCG testing whenever possible. The primary efficacy analysis will be based on the pregnancy Pearl Index, computed as the number of pregnancies that occur during the treatment period multiplied by 100 and divided by the number of WY of treatment contributed to the Treated Analysis Set among women receiving injections in the abdomen or thigh.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Serum MPA Concentrations in a Subset of 120 Participants","description":"Pharmacokinetic endpoints include serum MPA concentrations at month 2, 3, 4, 8, and 12.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.503","spread":"0.263"},{"groupId":"OG001","value":"0.355","spread":"0.155"},{"groupId":"OG002","value":"0.490","spread":"0.264"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.367","spread":"0.145"},{"groupId":"OG001","value":"0.328","spread":"0.160"},{"groupId":"OG002","value":"0.337","spread":"0.180"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.299","spread":"0.131"},{"groupId":"OG001","value":"0.267","spread":"0.133"},{"groupId":"OG002","value":"0.248","spread":"0.105"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.455","spread":"0.159"},{"groupId":"OG001","value":"0.404","spread":"0.145"},{"groupId":"OG002","value":"0.305","spread":"0.125"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.502","spread":"0.148"},{"groupId":"OG001","value":"0.431","spread":"0.127"},{"groupId":"OG002","value":"0.362","spread":"0.155"}]}]}]},{"type":"SECONDARY","title":"Occurrence of Serious Adverse Events (SAEs) and Adverse Events (AEs) Leading to Product Withdrawal","description":"The overall safety of study drug will be assessed throughout the study by evaluating the occurrence of SAEs and AEs leading to product discontinuation, blood pressure and weight at regularly scheduled visits, and changes in bleeding pattern.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"14","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Acceptability of Sayana® Press","description":"Perception of bleeding patterns and other responses to acceptability questions will be summarized using descriptive statistics based on routine questions asked at regularly scheduled visits (enrollment, months 4 and 8, and final). Acceptability data collected during unscheduled visits are not included in this table.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"306","spread":null},{"groupId":"OG001","value":"313","spread":null},{"groupId":"OG002","value":"34","spread":null}]},{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"23","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Return to Ovulation After 12 Months of Use of Sayana Press When Injected Every Four Months.","description":"Return to ovulation among a subset of study participants who received month 4 and month 8 injections and plan to use non-hormonal methods of contraception, or no contraception for up to a maximum of 12 months from the last study injection. Ovulation is defined as a single elevated serum progesterone (P ≥4.7 ng/mL) or a confirmed pregnancy test.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"18.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"54.5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":355},"commonTop":["Menstruation Irregular","Injection Site Reaction","Amenorrhoea","Weight Decreased","Weight Increased"]}}}